BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatinbased chemotherapy

Details for Australian Patent Application No. 2009216723 (hide)

Owner PANGAEA BIOTECH, S.A.

Inventors Rosell Costa, Rafael; Taron Roca, Miguel

Agent Collison & Co

Pub. Number AU-A-2009216723

PCT Pub. Number WO2009/103779

Priority 08380054.0 21.02.08 EP

Filing date 20 February 2009

Wipo publication date 27 August 2009

International Classifications

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

16 September 2010 PCT application entered the National Phase

  PCT publication WO2009/103779 Priority application(s): WO2009/103779

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009216726-Means for improving agrobiological traits in a plant by providing a plant cell comprising in its chloroplasts enzymatic activities for converting glycolate into malate

2009216715-Packaging pouch